These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34060323)

  • 1. The role of nebivolol in the management of hypertensive patients: from pharmacological profile to treatment guidelines.
    Ferri C
    Future Cardiol; 2021 Nov; 17(8):1421-1433. PubMed ID: 34060323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.
    Agabiti Rosei E; Rizzoni D
    Drugs; 2007; 67(8):1097-107. PubMed ID: 17521213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.
    Kamp O; Metra M; Bugatti S; Bettari L; Dei Cas A; Petrini N; Dei Cas L
    Drugs; 2010; 70(1):41-56. PubMed ID: 20030424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol: third-generation beta-blockade.
    de Boer RA; Voors AA; van Veldhuisen DJ
    Expert Opin Pharmacother; 2007 Jul; 8(10):1539-50. PubMed ID: 17661735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J
    Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary effects of nebivolol.
    Dal Negro R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):329-34. PubMed ID: 19638367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
    Weiss R
    Vasc Health Risk Manag; 2006; 2(3):303-8. PubMed ID: 17326335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-blockers in the management of hypertension: focus on nebivolol.
    Wojciechowski D; Papademetriou V
    Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):471-9. PubMed ID: 18402537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: a review of its use in the management of hypertension and chronic heart failure.
    Moen MD; Wagstaff AJ
    Drugs; 2006; 66(10):1389-409; discussion 1410. PubMed ID: 16903772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M; Gupta Y; Jain S; Vardas P
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol: a review.
    Cockcroft J
    Expert Opin Pharmacother; 2004 Apr; 5(4):893-9. PubMed ID: 15102571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebivolol: a review of its clinical and pharmacological characteristics.
    Gielen W; Cleophas TJ; Agrawal R
    Int J Clin Pharmacol Ther; 2006 Aug; 44(8):344-57. PubMed ID: 16961165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial.
    Espinola-Klein C; Weisser G; Jagodzinski A; Savvidis S; Warnholtz A; Ostad MA; Gori T; Munzel T
    Hypertension; 2011 Aug; 58(2):148-54. PubMed ID: 21646599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.